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Abstract 
Background Estimation of the clinical probability of malignancy in patients with pulmonary 
nodules will facilitate early diagnosis, determine optimum patient management strategies and 
reduce overall costs. 
 Method Data from the UK Lung Cancer Screening (UKLS) trial were analysed. Multivariable 
logistic regression models were utilised to identify independent predictors and to develop a 
parsimonious model to estimate the probability of lung cancer in lung nodules detected at 
baseline, three month and twelve month repeat screening. 
Results Of 1994 participants that underwent CT scan, 1013 participants had a total of 5063 
lung nodules and 52 (2.6%) of the participants developed lung cancer during a median follow-
up of 4 years. Covariates that predict lung cancer in our model included female gender, asthma, 
bronchitis, asbestos exposure, history of previous cancer, early and late onset of family history 
of lung cancer, smoking duration, forced vital capacity, nodule type (pure ground glass and 
part solid) and volume as measured by semi-automated volumetry. The final model 
incorporating all predictors had excellent discrimination; area under the receiver-operating 
characteristic curve (AUC [95% CI] = 0.885 [0.880 to 0.889]). Internal validation suggested 
that the model will discriminate well when applied to new data (optimism-corrected AUC = 
0.882 [0.848-.907]). The risk model had a good calibration (goodness-of-fit χ(8) 8.13, P = 
0.42).  
Conclusions Our model may be utilised in estimating the probability of lung cancer in nodules 
detected at baseline, and three months and twelve months from baseline, allowing more 
efficient stratification of follow-up in population-based lung cancer screening programs.  
  
 3 
Key Messages 
• What is the key question? 
To develop a lung cancer pulmonary nodule risk model which incorporates volumetric 
measurements. 
• What is the bottom line? 
The UKLS pulmonary risk model has excellent discrimination; area under the receiver-
operating characteristic curve (AUC [95% CI] = 0.885 [0.880 to 0.889] and has good 
calibration (goodness-of-fit χ(8) 8.13, P = 0.42).  
• Why read on? 
The potential for the UKLS Nodule Risk Model (UKLS-NRM) is that it may be utilised in 
future national CT screening programmes, which incorporates volumetric measurements to 
identify malignant pulmonary nodules. 
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Introduction 
Lung cancer is the most common cause of cancer death in Europe and has the highest economic 
cost (€18·8 billion, 15% of overall cancer costs).1 All respiratory illness in the UK costed £11·1 
billion in 2014.2 Despite recent improvements, thought to be related to improved resection 
rates, 5-year survival for all stages is only 13%, but >80% for patients with stage 1a disease. 3-
5  The poor survival outcome is partly attributable to variation in resection rates but mainly due 
to late presentation of the disease when surgical resection or other treatment options are less 
effective.6  
 
Low Dose Computed Tomography (LDCT) is a viable screening tool for early lung 
cancer detection and mortality reduction. The USA-based National Lung Screening Trial 
(NLST) demonstrated a 20% reduction in lung cancer mortality relative to chest x-ray 
screening.7 Results of the on-going Dutch-Belgian NELSON trial and pooled European 
randomised controlled trials are awaited.8 In the NLST and other (smaller) trials, over 20% of 
LDCT-screened participants had indeterminate lung nodules (i.e. potentially cancerous, but of 
insufficient size to refer for treatment), and thus required further CT scans. Diagnostic 
stratification of indeterminate pulmonary nodules is currently based on radiological 
characterisation  including nodule diameter and/or volume and risk prediction models. Indeed 
two risk prediction models, used sequentially are recommended in the latest British Thoracic 
Society (BTS) guidelines9, the Brock University model, for nodules ≥300mm3 or ≥8mm 
diameter,10 and where the risk is estimated at >10%, the Herder model after PET-CT.11   
However, none of these models employ volumetry and all are for use at baseline. 
Nodule volumetry provides a more accurate assessment for baseline size and subsequent 
growth than diameter measurements.12  Nodule volume is the preferred method for evaluation 
in the BTS guidelines and recommended as a more accurate method in the latest Fleischner 
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Society guideline.13 It appears in several diagnostic algorithms but is insufficient in 
isolation.14,15 It is therefore crucial to improve strategies to quantify the risk of malignancy in 
‘indeterminate nodules’. This allows participants in screening programmes to be simply 
returned to the next planned screen and patients to be reliably advised about the need for follow-
up or referral for clinical work-up. 
There is a growing recognition of the potential utility of risk models to predict lung 
cancer risk in patients with pulmonary nodules, thus allowing more subjects to be monitored 
with low dose imaging rather than needing minimally invasive or invasive procedures.16,17 The 
characteristics of pulmonary nodules detected on screening CT scans may determine optimum 
patient management strategies because risk-based selection of patients have been reported to 
precisely delineate the benefits and harms of screening by accommodating detailed information 
on lung cancer risk factors.18  The aim of this study was to develop a model to predict the risk 
of lung cancer in screen detected pulmonary nodules detected at baseline, 3 month or 12 month 
interval CT screening.  
 
Methods 
Study design and participants 
The United Kingdom Lung Cancer Screening (UKLS) Trial is a multicentre randomised 
controlled pilot trial of LDCT screening versus standard care for the early detection of lung 
cancer in high-risk individuals.15,19,20 The UKLS was approved by the National Information 
Governance Board and ethical approval was given by the Liverpool Central Research Ethics 
Committee in 2010 (reference number 10/H1005/74). The trial was registered with the 
International Standard Randomised Controlled Trial Register under the reference 78513845.  
Primary care trust (PCT) records were used to approach 247,354 individuals aged 50–
75 years, residing in specific health care areas (Liverpool, Knowsley, Sefton, Cambridgeshire, 
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Peterborough and Bedfordshire) by letter to participate in the trial. The Liverpool Lung Project 
lung cancer risk prediction model (LLPv2) was utilised to calculate risk scores to identify those 
at high risk (≥5% over 5 years) of developing lung cancer.21 A total of 4055 high-risk 
individuals were recruited and randomised, 2028 into the CT arm (of whom 1994 underwent a 
CT) and 2027 received usual care. At the time of reporting the UKLS identified 1.7% lung 
cancers at baseline which was significantly higher than either the NELSON or NLST baseline 
data. This study presents the result of 1013 of the 1994 participants with at least one non-
calcified lung nodule at baseline, 3 month and 12 month repeat LDCT.   
 
Thoracic CT scans 
 Details of the CT scans have been described previously.20 Briefly, thoracic CT images were 
obtained from lung apices to bases, during suspended inspiration, in a single breath hold and 
without the administration of intravenous contrast. Images were reconstructed at 1 mm 
thickness at 0.7 mm increments, using a moderate spatial frequency kernel reconstruction 
algorithm. Acquisition parameters (kVp and mAs) varied according to body habitus to achieve 
a CT dose index below 4 milliGray. 
 
Reading methods 
All CT scans were read using the ‘LungCARE’ (LungCARE, version Somaris/5 VB 10A, 
Siemens Medical Solutions) on the Syngo Siemens workstation, which provides a value for 
nodule size based on volume. To optimise sensitivity and specificity, all baseline CT scans 
were read by two thoracic radiologists at both local (Liverpool Heart and Chest Hospital or 
Papworth Hospital) and central (Royal Brompton Hospital) sites.15 All discrepancies were 
resolved by a review from the third thoracic radiologist at the Royal Brompton site and after 
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reaching a consensus, a letter outlining the results of the scan is sent to the participant and their 
GP.15 
 
 
Nodules: classification and management 
 
The management of pulmonary nodules within the UKLS trial has been reported in detail in 
the full HTA report. 20  Four categories of nodules were reported (Figure 1, provides the full 
details for solid, part solid and pure ground glass nodules): Category1 (benign nodule <3mm, 
diam. 15mm3) ; Category 2 (Vol. 15- 49mm3 3-4.9mm); Category 3 ( Vol. 50-500mm3, 5- 
9.9mm); Category 4 (Vol. >500mm3 or >10mm). All Category 2, 3 and 4 nodules were included 
in this analysis. The number of nodules identified in each of the three Categories are shown in 
Table 2.  
 
All of the nodules identified in the baseline scan were re-analysed in the follow up CT scans at 
3 and 12 months, except the malignant ones which had been resected. Thus, all of the UKLS 
reported nodules at 3 or 12 months were originally matched with the baseline scan. Stable 
baseline nodules were only counted once, i.e. at baseline, however, if a nodule developed new 
characteristics at 3 or 12 months, they were excluded from the analysis. Significant growth of 
nodules was defined based on their percentage change in volume and volume doubling time 
(VDT); i.e. 25% increase in volume and VDT <400 days. 
 
 Readers identified up to a maximum of 20 non-calcified nodules per subject. Nodules were 
categorized as solid, part-solid or pure ground-glass (pGGN) and further classified into four 
categories based on size reflecting their probability of being malignant as depicted in Table 
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1.15 Solid nodule outline was also recorded as, smooth, polylobulated, spiculated or irregular. 
Smooth was defined as a continuous regular outline. Lobulation was defined as areas of 
bulging of the lesion contour. Spiculation was defined as the presence of strands extending 
from the lung margin into the lung parenchyma. Irregular was defined as not smooth, 
polylobulated or spiculated. pGGN are defined as a nodule composed of a focal area of hazy 
increased lung opacity that does not obscure the underlying structures.9 Whenever follow-up 
scans (at 3 or 12 months) were performed, the volume doubling time (VDT) of the solid 
nodule was calculated, in the cases where nodule segmentation was reliable at baseline and 
follow-up. In the UKLS, we used manual diameter for i) ground glass and part solid nodules, 
ii) subpleural nodules and iii) nodules where volumetry was recorded as being unreliable, 
these nodules were excluded from the analysis. 
 
The diagnosis of lung cancer was made by histopathological examination of the resected 
specimen, otherwise it was based on the radiological clinical diagnosis. Quality control of the 
specimen involved exchange of a representative haematoxylin and eosin-stained section from 
all cases between reference thoracic pathologists at Liverpool and Papworth. This was 
accompanied where necessary by any immunolabelled sections used in diagnosis and or 
classification of lesion. Sections were blinded reviewed and responses were exchanged with 
appropriate discussion in case of discordance. 
 
Statistical analyses 
Descriptive statistics were obtained and compared by using the χ2 test or the Fisher’s exact test 
for categorical variables. Complete case analysis i.e. omitting covariates with missing data in 
regression models could lead to bias.22 Therefore, multiple imputation (MI) of missing data by 
chain equations was performed to impute missing data across multiple covariates 
simultaneously. The MI process was implemented in three steps: (1) imputation step, (2) 
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analysis step and (3) pooling step. The results of the analyses were pooled by applying the 
Rubin’s rules.23 Graham et al., using simulations recommended the use of many more 
imputations than the classical recommendation of three to five imputations so we used 20 
imputations based on their recommendation.24 The results of the analyses with imputation of 
missing covariates were similar to that of complete case analyses (Supplementary Information 
Table S1). Multivariable logistic regression models were constructed to estimate the 
probability that lung nodules detected at baseline, 3 month or 12 month LDCT screening were 
malignant. Variable selection was informed by the known and potential risk factors for lung 
cancer in the literature, clinical importance, confounding, collinearity, model stability and 
statistical significance. Variables considered for inclusion included age, gender, BMI, history 
of respiratory diseases (asthma, bronchitis, emphysema, pneumonia, tuberculosis and COPD), 
exposure to asbestos, previous history of cancer excluding lung cancer, family history of lung 
cancer, previous CT scan, previous X-ray, forced expiratory volume in 1 second (FEV1) and 
forced vital capacity (FVC). In addition, we also considered available nodular characteristics 
including nodular volume, nodule location, nodule type and nodule count (intrapulmonary 
lymph nodes were not included). Volume doubling time was assessed but insufficient data 
available for the UKLS risk model analysis.  The multivariable model was built in two phases. 
First, all covariates with P ≤ 0.10 in the univariate analyses were considered for inclusion in 
the multivariable model. Second, a backward selection procedure with (P < 0.05) was used to 
choose the covariates in the final multivariable model.25 Covariates eliminated were re-entered 
in the final multivariable model, with adjustment for the remaining significant covariates to 
ensure that no omitted covariate significantly reduced the log likelihood χ2 of the model.25 The 
unit of analysis was undertaken on a per nodule basis and since some individuals had multiple 
nodules, the variances of effect estimates were adjusted for data clustering within individuals 
using the Huber-White robust (sandwich) variance estimator. 26 
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Nonlinear effects of continuous variables were evaluated using fractional 
polynomials.27 The performance of the multivariable model was quantified by assessing its 
discrimination and calibration. Discrimination (ability to classify correctly) was assessed using 
the area under the receiver-operating characteristics curve (AUC). Model calibration was 
evaluated using Hosmer-Lemeshow goodness of fit test, and the Deviance and Residual test.28 
The overall model performance was evaluated using the Brier score.29 Bootstrapping 
techniques were used for internal validation of the model and bootstrap samples were drawn 
200 times with replacement.30 Regression models were created in each bootstrap sample and 
tested on the original sample to obtain stable estimates of the optimism of the model, i.e., how 
much the model performance was expected to decrease when applied in new datasets.31-33 All 
analyses were performed using Stata®14.2 (StataCorp. 2015. Stata Statistical Software: 
Release 14. College Station, TX: StataCorp LP) and SAS®9.4 (SAS Institute Inc, Cary, NC).  
 
Results 
Of 1994 participants that underwent CT scan, 1013 participants had a total of 5063 lung 
nodules and included the 52 (2.6%) of the participants developed lung cancer during a median 
follow-up of 4 years. There were 979 Category 1 Patients who had no nodules reported as per 
UKLS Protocol.  The mean age of the 1013 participants is 67.8±4.1 years. There was no 
significant difference between the age of participants with benign and malignant nodules. In 
subjects with malignant nodules, a greater proportion were female that in those with benign 
nodules” (32.7% vs 26.4%). Participants with malignant nodules had a longer smoking duration 
than participants with benign nodules (44.4±7.7 vs 41.3±10.3) years. COPD was more common 
in participants with malignant nodules compared to those with benign nodules (17.3% vs 
2.5%). Patients with a malignant diagnosis had larger nodules than patients with benign nodules 
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(P <0.0001). Furthermore, there were significant differences between FEV1, FVC, volume, 
nodule counts and nodule types between benign and malignant nodules (Table 3).  
In univariate analysis, female gender (OR, 2.407; 95%CI, 1.819-3.185), smoking 
duration (OR, 2.407; 95%CI, 1.819-3.185), pneumonia (OR, 1.444; 95%CI, 1.093-1.908), 
asthma (OR, 1.764; 95%CI, 1.326-2.346), tuberculosis (OR, 2.026; 95%CI, 1.514-2.710), 
COPD (OR, 2.062; 95%CI, 1.549-2.744), family history of lung cancer, early onset (OR, 3.694; 
95%CI, 2.696-5.026); late onset (OR, 2.062; 95%CI, 1.508-2.820), BMI (OR, 0.963; 95%CI, 
0.933-0.994), FEV1 (OR, 0.289; 95%CI, 0.233-0.359), FVC (OR, 0.313; 95%CI, 0.262-
0.375), nodular volume (OR, 1.001; 95%CI, 1.001-1.001) and nodule counts (OR, 0.977; 
95%CI, 0.958-0.996), pGGN type (OR, 3.106; 95%CI, 1.674-5.764) were significantly 
associated with malignancy in a nodule.  
Table 4 presents the final multivariate logistic regression model. Age, female gender, 
asthma, bronchitis, exposure to asbestos, previous malignancy, family history of lung cancer 
(early and late onset), smoking duration, forced vital capacity nodule type (pGGN and PSN), 
nodule location (upper vs middle or lower lobe) and nodular volume were included in the 
model. The model had very good discrimination with an AUC of 0.885(95% CI, 0.880–0.889; 
Figure 2) and 0.882 (95% CI, 0.848–0.907) by internal validation with bootstrap resampling 
and correction for optimism. The Hosmer–Lemeshow goodness-of-fit test demonstrated an 
excellent calibration χ2(8) 8.13, P = 0.42. Likewise, the Deviance (P = 1.00) and Pearson 
goodness of fit (P = 0.223) statistics indicates that the fitted model is appropriate. The overall 
model performance evaluated using the Brier score gives a P -value = 0.034. 
 
Discussion 
The clinical management of pulmonary nodules is challenging because of the need to 
distinguish benign and potentially malignant nodules. These challenges will become more 
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widespread if LDCT national screening is introduced. In this study, we utilised data from the 
UKLS pilot trial to develop and internally validate a risk model for estimating the probability 
of lung cancer in pulmonary nodules detected utilising the baseline, three month and twelve-
month data, from baseline. Our model had very good discrimination, excellent calibration and 
overall model performance. and internally validated using bootstrapping. 
An increasing number of malignancy risk prediction models have been proposed for 
categorising indeterminate pulmonary nodules. Some of these models may be subject to biases 
due to small sample size and retrospective study design.34,35 However, some models have been 
evaluated and compared in external case series and some show good discrimination.36-38 The 
two models with the highest accuracy were recommended for use in the BTS guidelines.9-11  
Although our model gave values for discrimination and calibration comparable to the 
two models recommended in the BTS guidelines, we cannot directly compare it with these 
models because accuracy can vary considerably, within populations. However, our model can 
be easily incorporated into screening protocols because it included readily available, strong, 
and plausible covariates that have been implicated in the aetiology of lung cancer from our own 
and numerous other case–control and cohort studies. The model reported in this paper is novel, 
as it incorporates screen detected nodule volume in the risk prediction calculation. Nodule 
volume is considered to be more accurate and reproducible than diameter measurements,39 but 
its role in lung risk prediction models  from clinical trial data has not been previously been 
used.  A previous effort has been made to develop pulmonary risk model incorporating volume 
in a small cohort from one center, of 221 patents with a 37% malignancy. The co-authors 
provided three promising models, which correctly classified the predicted malignancy in 83-
88% of subjects.40    
 It can be hypothesized that nodule volume is superior to diameter at predicting 
malignancy because it is a parameter that reflects the size of the entire nodule. 
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Previous lung diseases such as asthma and bronchitis have been reported as risk factors 
for lung cancer.41-43 In our study, asthma and bronchitis were independent predictors of lung 
cancer in our final multivariable model. The reasoning why bronchitis was found to be 
significant but neither COPD or emphysema were significant may be explained by 
misclassification either when there is no disease or asthma is wrongly labelled as COPD. We 
are unable to confirm this from our data. A second reason is that our smoking data was 
relatively accurate, and there is some debate about whether COPD is a significant independent 
risk factor for lung cancer or merely a marker of smoking.43 However, the protective 
association of asthma with nodule malignancy observed in our study suggests our source data 
were at least detecting true asthma, as asthma is not thought to be an independent risk factor 
for cancer.  In a recent meta-analysis, asthma was associated with increased risk of lung cancer 
but misclassification may have been operative here.42 In contrast, our observation about 
bronchitis as an independent predictor of malignancy is in agreement with earlier studies in the 
literature.41 
Other risk factors for lung cancer earlier described in the literature such as occupational 
exposure to asbestos, previous malignancy, family history of lung cancer, smoking duration 
and FVC were also significantly associated with lung cancer in this study.21,44 Our observation 
that female gender is significantly associated with lung cancer is in agreement with the study 
by McWilliams et al.10 and also in the UK population43 Our observation that FVC is 
significantly inversely associated with lung cancer is supported by a recent study by Enomoto 
et al. In their study, they reported that low FVC predicts cytotoxic chemotherapy-associated 
acute exacerbation of interstitial lung disease in patients with lung cancer.44 In addition, 
nodular characteristics such as PGGN type and nodular volume were independent predictors 
of lung cancer. 
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Strengths of our study include its study design i.e. a randomised trial, the large number 
of nodules relative to the participants, a UK socioeconomic representative population, the use 
of volumetry and detailed information on the main risk factors (such as smoking and family 
history of lung cancer) was ascertained by closely supervised trained interviewers, using 
standardized questionnaires.20  
Limitations of this study are that we did not include spiculation in our model because 
of the low number of nodules with this feature reported by UKLS radiologists and we were 
unable to examine the effect of volume doubling time. A second limitation is that the model 
was developed from a cohort at a particularly high risk of lung cancer, which means there is a 
possibility that it will perform less well in populations at lower risk. Although the model was 
developed and internally validated using bootstrapping, a well-established method for internal 
validation that has been found to be superior to other internal validation techniques,30 the 
ultimate test will be validation in an independent population.33 In addition, the marked 
geographical variation in incidence rates of lung cancer warrants the evaluation of our model 
in geographically diverse populations. Another limitation is that we did not evaluate diameter 
in the model. However, while automated diameter measurements are available from volumetry 
applications, these measurements are not typically used in screening when reliable volume 
measurements are available. 
 
Advancement in high-throughput methodologies and routine digitisation of medical 
records and their application in molecular and genetic epidemiological studies have expanded 
the potential for “omic”-based risk prediction.45 In this era of big data, advance statistical 
techniques, machine learning and deep learning methodologies will continue to emerge so we 
therefore recommend future studies to explore the utilisation of these methodologies to 
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integrate omics, imaging, genetics with clinical and other phenotypic characteristics in order 
to produce robust predictive models that may expedite lung cancer in benign nodules. 
In conclusion, we have developed and internally validated a risk model for estimating 
the probability of lung cancer in nodules detected at baseline, three months and twelve months 
from baseline. The model is based on readily available, strong, and plausible covariates that 
have been implicated in the aetiology of lung cancer. The application of the UKLS Nodule 
Risk Model (UKLS-NRM) has the potential to be used in both the research and clinical setting, 
in CT screening studies utilising volumetric analysis. The application of our model in 
identifying nodules at high risk of developing lung cancer in population-based screening 
programs needs further study. 
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Table 1 Nodule: categories, morphology and management 
 
  
Categories Solid Non-solid or part solid Management 
Category 1 Nodules containing fat or with a 
benign pattern of calcification 
are considered benign. Nodules 
< 15 mm3 or if pleural or juxta 
pleural ≤ 3 mm.  
Including intrapulmonary 
nodules 
 No future action 
taken 
Category 2 Intraparenchymal nodules with a 
volume of 15-49 mm3. Pleural 
or juxtapleural nodules with a 
maximal diameter of 3.1- 
4.9mm. 
Nodules with a maximal non-
solid component diameter < 5 
mm. Where there is a solid 
component, the component 
volume is <15 mm3 
Follow-up CT scan 
at 12 months 
Category 3 Intraparenchymal nodules with a 
volume of 50-500 mm3. Pleural 
or juxtapleural nodules with a 
maximal diameter of 5-9.9mm. 
Nodules with a maximal non-
solid component diameter 5 -
10 mm. Where there is a solid 
component, the component 
volume is 15-500 mm3 
Follow-up CT scan 
at 3 months and 12 
months 
Category 4 Intraparenchymal nodules with a 
volume of >500 mm3. Pleural or 
juxtapleural nodules with a 
maximal diameter of ≥ 10 mm3. 
Nodules with a solid 
component with volume > 500 
mm3 
Immediate referral to 
multidisciplinary 
team 
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Table 2  Numbers of patients and nodules per UKLS  nodules categories 2, 3 and 4. 
 
 
Nodule categories Number of patients Number of nodules 
2 622 3065 
3 333 1865 
4 58 133 
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Table 3 Characteristics of UKLS screened participants with benign and malignant nodules  
Characteristics Benign nodules (n=961) 
Malignant nodules 
(n=52) 
 
P-values 
Mean Age (years) ±SD 67.9±4.1 67.1±4.0 0.292 
Gender 
Male 
Female 
 
707(73.6) 
254(26.4) 
 
35(67.3) 
17(32.7) 
0.320 
Smoking duration (years) ±SD 41.3±10.3 44.4±7.7 0.0229 
Prior diagnosis of pneumoniaa 
No  
Yes  
 
561(58.4) 
149(15.5) 
 
23(44.2) 
8(15.4) 
0.520 
 
Prior diagnosis of Bronchitisb 
No  
Yes 
 
529(55.0) 
223(23.2) 
 
18(34.6) 
18(34.6) 
0.010 
Prior diagnosis of asthmac 
No 
Yes 
 
603(62.7) 
126(13.1) 
 
26(50.0) 
9(17.3) 
0.201 
Prior diagnosis of tuberculosisd 
No 
Yes 
 
634(66.0) 
24(2.5) 
 
26(50.0) 
0(0.0) 
0.716 
Prior diagnosis of COPDe 
No 
Yes 
 
605(63.0) 
109(2.5) 
 
25(48.1) 
9(17.3) 
0.080 
Occupational exposure to asbestosf  
No 
Yes 
 
526(58.9) 
366(38.1) 
 
29(55.8) 
14(26.9) 
0.269 
Prior diagnosis of malignant tumourg 
No 
Yes 
 
773(80.4) 
187(19.5) 
 
40(76.9) 
12(23.1) 
0.525 
 
Family history of lung cancerh 
No 
Early onset * 
Late onset* 
 
721(75.0) 
93(9.7) 
146(15.2) 
 
31(59.6) 
10(19.2) 
11(21.2) 
0.028 
 
BMI (kg/m2) 26.9±4.6 26.5±5.3 0.485 
FEV1(Litres) 2.46±0.74 1.89±0.54 <0.0001 
FVC (Litres) 3.49±0.92 2.63±0.67 <0.0001 
Nodular volume (mm3) (Median, 
IQR) 34.5 (21.0-70.5)   320.0 (49.5-1407.4) <0.0001 
Nodule counts 7.0±8.5 8.0±5.9 0.0193 
Nodule location 
Upper 
Middle or lower lobe 
 
573 
388 
 
33 
19 
0.583 
Nodule type (solid as reference) 
Nonsolid  
Part solid 
 
947 
4 
 
49 
3 
0.023 
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Abbreviations: (a, b, c, d, e, f, g, h indicates the percentage of missingness in covariates; a=26%, 
b=22%, c=24%, d=32%, e=26%, f=7.2%, g=0.1%, h=0.1%); COPD= chronic obstructive pulmonary 
disease.  Family history early <60 years : late is 60 years and above.   
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Table 4 Regression coefficients, OR (95%CI) and SE for covariates in the final model for the 
probability of lung cancer in pulmonary nodules 
*Family history early <60 years: late is 60 years and above. 
Note, Multiple imputations used in this analysis 
  
Covariates β-coefficient Standard error OR (95%CI) P-values 
Intercept 
 
Age (years) 
 
-2.2915 
 
-0.0257 
1.2921 
 
0.0174 
 
- 
 
0.975(0.942-1.008) 
 
0.076 
 
0.138 
 
Gender (female) 
 
Asthma 
 
0.5105 
 
-0.7777 
0.1653 
 
0.2093 
 
1.666(1.205-2.304) 
 
0.459(0.305-0.693) 
 
0.002 
 
<0.0001 
Bronchitis 
 
1.7616 0.2052 
 
5.823(3.894-8.704) 
 
<0.0001 
Asbestos exposure 
 
Previous malignancy 
0.5884 
 
0.5305 
0.1855 
 
0.1824 
1.801(1.252-2.591) 
 
1.699(1.189-2.430) 
0.002 
 
0.004 
Family history of cancer 
Early onset * 
Late onset* 
 
1.9985 
1.5724 
 
0.2158 
0.2055 
 
7.378(4.834-11.262) 
4.818(3.220-7.209) 
 
<0.0001 
<0.0001 
Smoking duration (years) 0.0565 0.0097 
 
1.059(1.038-1.078) 
 
<0.0001 
 
Forced vital capacity (Litres) -1.1693 0.1108 0.311(0.250-0.386) <0.0001 
 
Nodule type (solid as reference) 
Nonsolid  
Part solid 
 
 
1.6396 
0.4919 
 
 
0.3370 
0.2837 
 
 
5.153(2.662-9.976) 
1.635(0.938-2.852) 
 
 
<0.0001 
0.083 
 
Nodule location 
Upper vs. middle or lower lobe 
 
-0.1799 
 
0.1607 
 
0.835(0.610-1.144) 
 
0.263 
Nodular volume (mm3) 0.000822 0.000186 1.001(1.000-1.001) <0.0001 
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Figure 1 
The UKLS nodule care pathway management protocol 
 
Reproduced from;  Field JK, Duffy SW, Baldwin DR, et al. The UK Lung Cancer Screening Trial: a 
pilot randomised controlled trial of low-dose computed tomography screening for the early detection of 
lung cancer. Health Technol Assess 2016; 20(40): 1-146. 
 
 
 
 
Figure 2 
Receiver operating curve for the UKLS Nodule risk model 
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Area under ROC curve = 0.885 (95%CI 0.880 - 0.889)
